Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03504488
Recruitment Status : Recruiting
First Posted : April 20, 2018
Last Update Posted : July 20, 2022
Sponsor:
Information provided by (Responsible Party):
BioAtla, Inc.

Brief Summary:
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Triple Negative Breast Cancer Melanoma Head and Neck Cancer Biological: CAB-ROR2-ADC Biological: PD-1 inhibitor Phase 1 Phase 2

Detailed Description:

This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3021, a conditionally active biologic (CAB) ROR2-targeted antibody drug conjugate (CAB-ROR2-ADC) BA3021 in patients with advanced solid tumors.

This study will consist of a dose escalation phase and a dose expansion phase with BA3021 in Phase 1. Phase 2 will study BA3021 alone or in combination with a PD-1 inhibitor.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 420 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Actual Study Start Date : June 27, 2018
Estimated Primary Completion Date : March 30, 2023
Estimated Study Completion Date : June 30, 2023


Arm Intervention/treatment
Experimental: Monotherapy - CAB-ROR2-ADC (BA3021) alone
BA3021 alone
Biological: CAB-ROR2-ADC
Conditionally active biologic anti-ROR2 antibody drug conjugate
Other Name: BA3021

Experimental: Combination Therapy
CAB-ROR2-ADC (BA3021) with PD-1 inhibitor
Biological: CAB-ROR2-ADC
Conditionally active biologic anti-ROR2 antibody drug conjugate
Other Name: BA3021

Biological: PD-1 inhibitor
PD-1 inhibitor




Primary Outcome Measures :
  1. Phase 1: Safety Profile [ Time Frame: Up to 24 months ]
    Assess dose limiting toxicity as defined in the protocol

  2. Phase 1: Safety Profile [ Time Frame: Up to 24 months ]
    Assess maximum tolerated dose as defined in the protocol

  3. Phase 1 and 2: Safety Profile [ Time Frame: Up to 24 months ]
    Frequency and severity of AEs and/or SAEs

  4. Phase 2: Confirmed Objective Response Rate (ORR) [ Time Frame: Up to 24 months ]
    Proportion of patients who achieve a confirmed CR or PR


Secondary Outcome Measures :
  1. Phase 1: Pharmacokinetics [ Time Frame: Up to 24 months ]
    Plasma concentrations of ADC, total antibody and MMAE

  2. Phase 1: Pharmacokinetics [ Time Frame: Up to 24 months ]
    Peak Plasma Concentration (Cmax)

  3. Phase 1: Pharmacokinetics [ Time Frame: Up to 24 months ]
    Area under the plasma concentration versus time curve

  4. Phase 1: Confirmed Objective Response Rate (ORR) [ Time Frame: Up to 24 months ]
    Proportion of patients who achieve a confirmed CR or PR

  5. Phase 1: Immunogenicity [ Time Frame: Up to 24 months ]
    The number and percentage of patients who develop detectable anti-drug antibodies (ADAs)

  6. Phase 1 and 2: Duration of response (DOR) [ Time Frame: Up to 24 months ]
    Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first

  7. Phase 1 and 2: Progression-free survival (PFS) [ Time Frame: Up to 24 months ]
    Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first

  8. Phase 1 and 2: Best overall response (OR) [ Time Frame: Up to 24 months ]
    All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy

  9. Phase 1 and 2: Disease control rate (DCR) [ Time Frame: Up to 24 months ]
    Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks

  10. Phase 1 and 2: Time to response (TTR) [ Time Frame: Up to 24 months ]
    Time from the first dose of investigational product until the first documentation of OR

  11. Phase 1 and 2: Overall survival (OS) [ Time Frame: Up to 24 months ]
    Time from the first dose of BA3021 treatment until death due to any cause

  12. Phase 1 and 2: Tumor size [ Time Frame: Up to 24 months ]
    Percent change from baseline in tumor size



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse standard therapy.
  • Patients must have measurable disease.
  • For the dose expansion phase: Patients with locally advanced unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) and soft tissue sarcoma (STS)
  • Age ≥ 18 years.
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of at least three months.

Exclusion Criteria:

  • Patients must not have clinically significant cardiac disease.
  • Patients must not have known non-controlled CNS metastasis.
  • Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
  • Patients must not have had major surgery within 4 weeks before first BA3021 administration.
  • Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
  • Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
  • Patients must not be women who are pregnant or breast feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03504488


Contacts
Layout table for location contacts
Contact: Hazel Buncab 858-263-1598 ext 8582631598 hbuncab@bioatla.com
Contact: Ji Hwan Lee 858-286-7702 jlee@bioatla.com

Locations
Show Show 41 study locations
Sponsors and Collaborators
BioAtla, Inc.
Investigators
Layout table for investigator information
Study Director: Philippe Martin BioAtla, Inc.
Layout table for additonal information
Responsible Party: BioAtla, Inc.
ClinicalTrials.gov Identifier: NCT03504488    
Other Study ID Numbers: BA3021-001
First Posted: April 20, 2018    Key Record Dates
Last Update Posted: July 20, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Head and Neck Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Breast Neoplasms
Breast Diseases
Skin Diseases
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Antineoplastic Agents